Loading search results…

Scholars @ Weill Cornell Medicine

Help & supportPhase 1 prototype

Browse

Scholars8,803 Publications201,348 Funding7,268 Clinical research61

Loading search results…

Browse

Scholars8,803 Publications201,348 Funding7,268 Clinical research61

FiltersClear all

Status

Recruiting18
Active, not recruiting33
Completed7
Terminated3

Study type

Interventional61

Phase

Phase 325
Phase 219
Not applicable8
Phase 1/24
Phase 2/34
Phase 11

Investigator

Hani Lamie Ashamalla10
Silvia Chiara Formenti7
Eleni Andreopoulou5
Alexander Ja-Ho Chou3
John Ng3

Department

Radiation Oncology25
Medicine20
Pediatrics8
Neurology2
Urology2

Show all 9

Condition

Breast Neoplasms14
Prostatic Neoplasms11
Brain Neoplasms3
Burkitt Lymphoma3
Carcinoma, Non-Small-Cell Lung3

Intervention type

Radiation61
Drug788
Other176
Device166
Biological150
Procedure119

Sponsor type

NIH18
WCM (investigator-initiated)17
Other academic14
Industry6
Cooperative group6

Start date

Has results posted14

Interventional×Radiation×Clear all

Showing 1–20 of 61 studiesSort:

Active, not recruitingInterventional · Phase 3NCT01901094 ↗
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

FiltersClear all

Status

Recruiting18
Active, not recruiting33
Completed7
Terminated3

Study type

Interventional61

Phase

Phase 325
Phase 219
Not applicable8
Phase 1/24
Phase 2/34
Phase 11

Investigator

Hani Lamie Ashamalla10
Silvia Chiara Formenti7
Eleni Andreopoulou5
Alexander Ja-Ho Chou3
John Ng3

Department

Radiation Oncology25
Medicine20
Pediatrics8
Neurology2
Urology2

Show all 9

Condition

Breast Neoplasms14
Prostatic Neoplasms11
Brain Neoplasms3
Burkitt Lymphoma3
Carcinoma, Non-Small-Cell Lung3

Intervention type

Radiation61
Drug788
Other176
Device166
Biological150
Procedure119

Sponsor type

NIH18
WCM (investigator-initiated)17
Other academic14
Industry6
Cooperative group6

Start date

Has results posted14

Interventional×Radiation×Clear all

Showing 1–20 of 61 studiesSort:

Active, not recruitingInterventional · Phase 3NCT01901094 ↗
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

Show all 32

Show fewer

Manish A Shah3
Scott T. Tagawa3
Emily Weg2
Jaclyn Rosenzweig2
Nitya Gulati2
Ashish Saxena1
Allyson J Ocean1
Alexandra Gomez Arteaga1
Ana M. Molina1
Baoqing Li1
David A. Green1
Doru Paul1
Douglas S Scherr1
Elizabeta Cristina Popa1
Encouse Golden1
Evelyn Cantillo1
Gunisha Kaur1
Howard Alan Fine1
Jia Ruan1
Lauren Elreda1
Lisa Giulino Roth1
Nasser K Altorki1
Rajiv S. Magge1
Raymond Luke1
Rohit Kumar Jain1
Gene Kim1
Uqba Khan1

Show fewer

Anesthesiology1
Cardiothoracic Surgery1
Obstetrics and Gynecology1
Radiology1

Show all 40

Show fewer

Lung Neoplasms3
Pancreatic Neoplasms3
Adenocarcinoma Of Esophagus2
Carcinoma, Renal Cell2
Head and Neck Neoplasms2
Hodgkin Disease2
Neoplasm Metastasis2
Parkinson Disease 4, Autosomal Dominant Lewy Body2
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma2
Rectal Neoplasms2
Triple Negative Breast Neoplasms2
Urinary Bladder Neoplasms2
Breast Carcinoma In Situ1
Bronchial Neoplasms1
Carcinoma, Bronchogenic1
Carcinoma, Transitional Cell1
Carcinosarcoma1
Cholangiocarcinoma1
Colorectal Neoplasms1
Down Syndrome1
Esophageal Squamous Cell Carcinoma1
Gallbladder Neoplasms1
Glioblastoma1
Gliosarcoma1
Hematologic Neoplasms1
Leukemia, Biphenotypic, Acute1
Melanoma1
Neoplasms1
Oropharyngeal Neoplasms1
Rhabdomyosarcoma1
Rhabdomyosarcoma, Alveolar1
Rhabdomyosarcoma, Embryonal1
Small Cell Lung Carcinoma1
Tachycardia, Ventricular1
Wilms Tumor1

Behavioral83

Diagnostic test22

Dietary supplement14

Combination product11

Genetic6

Eleni AndreopoulouPI

Intervention: Procedure: Axillary Lymph Node Dissection (ALND) · Radiation: Nodal Radiation Therapy · Radiation: Axillary Radiation Therapy
Dates: Feb 2014 – Jan 2031 (est.)
Sponsor: Alliance for Clinical Trials in Oncology

Stage II Breast CancerStage IIIA Breast Cancer

Active, not recruitingInterventional · Phase 3NCT02954874 ↗

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy

Eleni AndreopoulouPI

Intervention: Procedure: Biospecimen Collection · Other: Laboratory Biomarker Analysis · Other: Patient Observation · Biological: Pembrolizumab · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Radiation: Radiation Therapy
Dates: Jan 2017 – Aug 2026
Sponsor: Southwest Oncology Group

Breast Carcinoma In SituInvasive Breast CarcinomaStage I Breast Cancer AJCC v7+3 more

Active, not recruitingInterventional · Phase 2NCT03371719 ↗

A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)

Hani Lamie AshamallaPI

Intervention: Drug: Apalutamide · Radiation: External Beam Radiation Therapy · Other: Placebo Administration
Dates: Jun 2018 – Mar 2025· Results posted
Sponsor: NRG Oncology

Recurrent Prostate CarcinomaStage III Prostate Adenocarcinoma AJCC v7Stage IV Prostate Adenocarcinoma AJCC v7

Active, not recruitingInterventional · Phase 2NCT03407144 ↗

An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults With Newly Diagnosed Classical Hodgkin Lymphoma With Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)

Lisa Giulino RothPI

Intervention: Biological: pembrolizumab · Drug: doxorubicin · Drug: vinblastine · Drug: dacarbazine · Drug: cyclophosphamide · Drug: vincristine · Drug: prednisone/prednisolone · Drug: bleomycin · Drug: etoposide · Radiation: Radiotherapy (RT)
Dates: Apr 2018 – Feb 2027 (est.)
Sponsor: Children's Oncology Group

Hodgkin Lymphoma

Active, not recruitingInterventional · Phase 3NCT03488693 ↗

TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

Hani Lamie AshamallaPI

Intervention: Radiation: Radiation · Other: No Radiation
Dates: Oct 2018 – Sep 2027 (est.)
Sponsor: Canadian Cancer Trials Group

Breast Cancer

Active, not recruitingInterventional · Not applicableNCT03561220 ↗

A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer

Baoqing LiPI

Intervention: Radiation: Standard of Care IMRT (Photon) · Radiation: Standard of Care Proton Therapy · Radiation: Proton Arm 1: Standard Proton Therapy · Radiation: Proton Arm 2: Hypofractionated Proton Therapy
Dates: Jul 2018 – Feb 2026
Sponsor: University of Florida Health - Jacksonville

Prostate Cancer

Active, not recruitingInterventional · Phase 2/3NCT03604991 ↗

A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma

Manish A ShahPI

Intervention: Procedure: Biospecimen Collection · Drug: Carboplatin · Procedure: Computed Tomography · Biological: Ipilimumab · Biological: Nivolumab · Drug: Paclitaxel · Procedure: Positron Emission Tomography · Radiation: Radiation Therapy
Dates: May 2019 – Mar 2027 (est.)
Sponsor: ECOG-ACRIN Cancer Research Group

Clinical Stage II Esophageal Adenocarcinoma AJCC v8Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage III Esophageal Adenocarcinoma AJCC v8+5 more

Active, not recruitingInterventional · Not applicableNCT03621644 ↗

Prospective Phase II Study of Stereotactic Magnetic Resonance Imaging (MRI) Guided On-table Adaptive Radiation Therapy (SMART) for Patients With Borderline or Inoperable Locally Advanced Pancreatic Cancer

John NgPI

Intervention: Radiation: Stereotactic MRI-guided On-table Adaptive Radiation Therapy
Dates: Jan 2019 – Aug 2022
Sponsor: ViewRay Technologies, Inc

Pancreatic Cancer

RecruitingInterventional · Phase 3NCT03678025 ↗

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

Douglas S ScherrPI

Intervention: Drug: Abiraterone · Drug: Bicalutamide · Drug: Degarelix · Drug: Docetaxel · Drug: Flutamide · Drug: Goserelin Acetate · Drug: Histrelin Acetate · Drug: Leuprolide Acetate · Drug: Nilutamide · Procedure: Orchiectomy · Drug: Prednisone · Other: Quality-of-Life Assessment · Radiation: Radiation Therapy · Procedure: Radical Prostatectomy · Drug: Triptorelin
Dates: Sep 2018 – Apr 2033 (est.)
Sponsor: Southwest Oncology Group

Castration Levels of TestosteroneMetastatic Prostatic AdenocarcinomaStage IV Prostate Cancer AJCC v8+2 more

Active, not recruitingInterventional · Phase 3NCT03725059 ↗

A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (KEYNOTE-756)

Eleni AndreopoulouPI

Intervention: Biological: Pembrolizumab (K) · Drug: Placebo (P) · Drug: Paclitaxel (X) · Drug: Doxorubicin (A) · Drug: Epirubicin (E) · Drug: Cyclophosphamide (C) · Drug: Endocrine therapy · Radiation: Radiation therapy · Procedure: Surgery
Dates: Dec 2018 – Jan 2031 (est.)
Sponsor: Merck & Co., Inc.

Breast Cancer

Active, not recruitingInterventional · Phase 3NCT03765918 ↗

A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)

Doru PaulPI

Intervention: Biological: Pembrolizumab 200 mg · Radiation: Radiotherapy 60 Gray · Radiation: Radiotherapy 66 Gray · Radiation: Radiotherapy 70 Gray · Drug: Cisplatin 100 mg/m^2
Dates: Dec 2018 – Jul 2024· Results posted
Sponsor: Merck Sharp & Dohme Corp

Head and Neck Neoplasms

RecruitingInterventional · Phase 2NCT03804944 ↗

Converting HR+ Breast Cancer Into an Individualized Vaccine

Silvia Chiara FormentiPI

Intervention: Radiation: Focal Radiation therapy · Drug: Pembrolizumab (200mg IV for 30 minutes · Biological: CDX-301
Dates: Mar 2020 – Dec 2026 (est.)
Sponsor: Weill Medical College of Cornell University

Breast Cancer

Active, not recruitingInterventional · Phase 3NCT03811015 ↗

A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC

Hani Lamie AshamallaPI

Intervention: Procedure: Biospecimen Collection · Drug: Cisplatin · Procedure: Computed Tomography · Procedure: Echocardiography Test · Other: Fludeoxyglucose F-18 · Radiation: Intensity-Modulated Radiation Therapy · Biological: Nivolumab · Other: Patient Observation · Procedure: Positron Emission Tomography
Dates: Aug 2019 – Jan 2030 (est.)
Sponsor: ECOG-ACRIN Cancer Research Group

Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

Active, not recruitingInterventional · Phase 3NCT03907488 ↗

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Jia RuanPI

Intervention: Procedure: Biospecimen Collection · Drug: Brentuximab Vedotin · Procedure: Computed Tomography · Drug: Dacarbazine · Drug: Doxorubicin Hydrochloride · Biological: Filgrastim · Procedure: Magnetic Resonance Imaging · Biological: Nivolumab · Biological: Pegfilgrastim · Procedure: Positron Emission Tomography · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Radiation: Radiation Therapy · Drug: Vinblastine Sulfate
Dates: Aug 2019 – Mar 2024· Results posted
Sponsor: Southwest Oncology Group

Ann Arbor Stage III Hodgkin LymphomaAnn Arbor Stage III Lymphocyte-Depleted Classic Hodgkin LymphomaAnn Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma+7 more

Active, not recruitingInterventional · Phase 3NCT03914625 ↗

A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)

Alexander Ja-Ho ChouPI

Intervention: Drug: Asparaginase Erwinia chrysanthemi · Biological: Blinatumomab · Drug: Cyclophosphamide · Drug: Cytarabine · Drug: Dexamethasone · Drug: Doxorubicin Hydrochloride · Drug: Leucovorin Calcium · Drug: Mercaptopurine · Drug: Mercaptopurine Oral Suspension · Drug: Methotrexate · Drug: Pegaspargase · Drug: Prednisolone · Drug: Prednisone · Radiation: Radiation Therapy · Drug: Thioguanine · Drug: Vincristine Sulfate
Dates: Jul 2019 – Sep 2027 (est.)
Sponsor: Children's Oncology Group

B Acute Lymphoblastic LeukemiaB Lymphoblastic LymphomaDown Syndrome

RecruitingInterventional · Phase 3NCT03959085 ↗

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

Jaclyn RosenzweigPI

Intervention: Procedure: Biospecimen Collection · Biological: Blinatumomab · Procedure: Bone Marrow Aspiration · Procedure: Bone Marrow Biopsy · Procedure: Bone Scan · Drug: Calaspargase Pegol · Procedure: Computed Tomography · Drug: Cyclophosphamide · Drug: Cytarabine · Drug: Daunorubicin Hydrochloride · Drug: Dexamethasone · Drug: Doxorubicin Hydrochloride · Biological: Inotuzumab Ozogamicin · Drug: Leucovorin Calcium · Procedure: Magnetic Resonance Imaging · Drug: Mercaptopurine · Drug: Methotrexate · Drug: Pegaspargase · Procedure: Positron Emission Tomography · Drug: Prednisolone · Drug: Prednisone · Other: Questionnaire Administration · Radiation: Radiation Therapy · Drug: Thioguanine · Drug: Vincristine Sulfate
Dates: Oct 2019 – Mar 2032 (est.)
Sponsor: Children's Oncology Group

B Acute Lymphoblastic LeukemiaB Lymphoblastic LymphomaCentral Nervous System Leukemia+2 more

Active, not recruitingInterventional · Phase 1NCT04052555 ↗

A Phase 1b Study of Berzosertib in Combination With Radiation Therapy to Overcome Therapeutic Resistance in Chemotherapy Resistant Triple Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer

Eleni AndreopoulouPI

Intervention: Drug: Berzosertib · Procedure: Biospecimen Collection · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Radiation: Radiation Therapy
Dates: Sep 2020 – Feb 2027 (est.)
Sponsor: National Cancer Institute

Bilateral Breast CarcinomaHER2-Negative Breast CarcinomaLocalized Breast Carcinoma+2 more

Active, not recruitingInterventional · Phase 1/2NCT04068194 ↗

A Phase I/II Study of M3814 and Avelumab in Combination With Hypofractionated Radiation in Patients With Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

Elizabeta Cristina PopaPI

Intervention: Drug: Avelumab · Procedure: Biopsy Procedure · Procedure: Biospecimen Collection · Procedure: Computed Tomography · Radiation: Hypofractionated Radiation Therapy · Drug: Peposertib
Dates: Apr 2020 – Jul 2027 (est.)
Sponsor: National Cancer Institute

Locally Advanced Malignant Solid NeoplasmLocally Advanced Unresectable CholangiocarcinomaLocally Advanced Unresectable Gallbladder Carcinoma+7 more

Active, not recruitingInterventional · Phase 2NCT04071223 ↗

A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Advanced Renal Cell Carcinoma With Bone Metastasis (RadiCal)

Ana M. MolinaPI

Intervention: Procedure: Biospecimen Collection · Procedure: Bone Scan · Drug: Cabozantinib S-malate · Procedure: Computed Tomography · Procedure: Magnetic Resonance Imaging · Procedure: Positron Emission Tomography · Other: Questionnaire Administration · Radiation: Radium Ra 223 Dichloride
Dates: Jul 2020 – Jul 2026
Sponsor: Alliance for Clinical Trials in Oncology

Advanced Renal Cell CarcinomaChromophobe Renal Cell CarcinomaClear Cell Renal Cell Carcinoma+6 more

Active, not recruitingInterventional · Phase 1/2NCT04172532 ↗

A Phase 1/2 Study of M3814 (Peposertib) in Combination With Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma

Allyson J OceanPI

Intervention: Procedure: Biopsy Procedure · Procedure: Biospecimen Collection · Procedure: Computed Tomography · Radiation: Hypofractionated Radiation Therapy · Procedure: Magnetic Resonance Imaging · Drug: Peposertib · Other: Placebo Administration
Dates: Jan 2021 – Aug 2027 (est.)
Sponsor: National Cancer Institute

Locally Advanced Pancreatic AdenocarcinomaStage III Pancreatic Cancer AJCC v8

‹ Prev1 2 3 4 Next ›